GENIL Stock Overview
A pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₺121.70 |
| 52 Week High | ₺124.70 |
| 52 Week Low | ₺51.95 |
| Beta | 1.1 |
| 1 Month Change | 1.42% |
| 3 Month Change | 46.19% |
| 1 Year Change | 130.71% |
| 3 Year Change | 635.35% |
| 5 Year Change | n/a |
| Change since IPO | 929.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENIL | TR Pharmaceuticals | TR Market | |
|---|---|---|---|
| 7D | 6.9% | -0.7% | -1.6% |
| 1Y | 130.7% | 10.3% | 12.3% |
Return vs Industry: GENIL exceeded the TR Pharmaceuticals industry which returned 8.5% over the past year.
Return vs Market: GENIL exceeded the TR Market which returned 13.9% over the past year.
Price Volatility
| GENIL volatility | |
|---|---|
| GENIL Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in TR Market | 8.1% |
| 10% least volatile stocks in TR Market | 3.9% |
Stable Share Price: GENIL has not had significant price volatility in the past 3 months compared to the TR market.
Volatility Over Time: GENIL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 626 | Abidin Gulmus | www.genilac.com.tr |
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Fundamentals Summary
| GENIL fundamental statistics | |
|---|---|
| Market cap | ₺34.74b |
| Earnings (TTM) | ₺558.54m |
| Revenue (TTM) | ₺11.21b |
65.4x
P/E Ratio3.3x
P/S RatioIs GENIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENIL income statement (TTM) | |
|---|---|
| Revenue | ₺11.21b |
| Cost of Revenue | ₺9.00b |
| Gross Profit | ₺2.21b |
| Other Expenses | ₺1.65b |
| Earnings | ₺558.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.86 |
| Gross Margin | 19.72% |
| Net Profit Margin | 4.98% |
| Debt/Equity Ratio | 24.4% |
How did GENIL perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 08:07 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|